COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04452318 |
Recruitment Status :
Completed
First Posted : June 30, 2020
Last Update Posted : October 7, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Primary Objectives:
Cohort A:
• To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing symptomatic SARS-CoV-2 infection (broad-term) confirmed by RT-qPCR
Cohort A and Cohort A1:
• To evaluate the safety and tolerability of REGN10933+REGN10987 following subcutaneous (SC) administration compared to placebo
Cohort B • To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing COVID-19 symptoms (broad-term)
Cohort B and Cohort B1
• To evaluate the safety and tolerability of REGN10933+REGN10987 following SC administration compared to placebo
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy Participants | Drug: REGN10933 + REGN10987 Drug: Placebo | Phase 3 |
Cohort A: adult and adolescent subjects (≥12 years) who are SARS -CoV-2 RT-qPCR negative at baseline
Cohort A1: pediatric subjects (<12 years) who are SARS-CoV-2 RT--qPCR negative at baseline
Cohort B: adult and adolescent subjects (≥12 years) who are SARS -CoV-2 RT-qPCR positive at baseline
Cohort B1: pediatric subjects (<12 years) who are SARS-CoV-2 RT--qPCR positive at baseline
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 3303 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected With SARS-CoV-2 |
Actual Study Start Date : | July 13, 2020 |
Actual Primary Completion Date : | October 4, 2021 |
Actual Study Completion Date : | October 4, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: REGN10933 + REGN10987 |
Drug: REGN10933 + REGN10987
Subcutaneous (SC) or Intramuscular (IM) injections
Other Names:
|
Placebo Comparator: Placebo |
Drug: Placebo
SC or IM injections |
- Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad-term) during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A
- Proportion of participants with treatment-emergent adverse events (TEAEs) and severity of TEAEs [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants who subsequently develop signs and symptoms (broad-term) within 14 days of a positive RT-qPCR at baseline or during the EAP [ Time Frame: Up to 1 month ]
For all subject irrespective of baseline serology status (based on central lab test)
Cohort B
- Proportion of participants with a viral load >4 (log10 copies/mL) in Nasopharyngeal (NP) swab samples during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Number of weeks of symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad term) during the EAP [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Number of weeks of high viral load >4 (log10 copies/mL) in NP swab samples during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Number of weeks of RT-qPCR confirmed SARS-CoV-2 infection (regardless of symptoms) during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants who have a RT-qPCR confirmed SARS-CoV-2 infection (regardless of symptoms) during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants in placebo group with a RT-qPCR confirmed SARS-CoV-2 infection during the EAP with an index case participating in study R10933-10987-COV-2067 (NCT04425629) [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (CDC definition) during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Number of weeks of symptomatic RT-qPCR-confirmed SARS-CoV-2 infection (CDC definition) during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (strict-term) during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Number of weeks of symptomatic RT-qPCR confirmed SARS-CoV-2 infection (strict-term) during the EAP [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants who have a RT-qPCR confirmed SARS-CoV-2 infections at each week in the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad-term) at each week in the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Time-weighted average of viral load (log10 copies/mL) from the first positive SARS CoV-2 RT-qPCR in NP swab samples (that has an onset during the EAP) until the third weekly visit after the first positive test during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Time-weighted average of viral load (log10 copies/mL) from the first positive SARS-CoV-2 RT-qPCR in NP swab samples (that has an onset during the EAP) until the second weekly visit after the first positive test during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Maximum SARS-CoV-2 RT-qPCR viral load (log10 copies/mL) in NP swab samples among individuals with ≥1 RT-qPCR positive that has an onset during the EAP [ Time Frame: Up to1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- SARS-CoV-2 RT-qPCR viral load (log10 copies/mL) in NP swab samples corresponding to the onset of first positive RT-qPCR during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Area under the curve (AUC) in viral load (log10 copies/mL) from the first positive SARS-CoV-2 RT-qPCR NP swab samples detected during the EAP until the first confirmed negative test [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Number of medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants with at least 1 COVID-19-related hospitalization or emergency room visit associated with a positive RT-qPCR during the EAP or all-cause death [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection that has an onset during the EAP [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Number of days missed for daily responsibilities (where applicable) due to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset during the EAP [ Time Frame: Up to 8 months ]
Daily responsibilities including work (employed adults) or school (students), daycare or family obligations/responsibilities (childcare or eldercare)
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of participants in the placebo group with a RT-qPCR confirmed SARS-CoV-2 infection during the EAP with at least 1 household member participating either in study R10933-10987-COV-2067 (NCT04425629) or in cohort B [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Proportion of subjects who have a symptomatic RT-qPCR confirmed SARS-CoV-2 infection (broad-term) during the EAP [ Time Frame: Up to 1 month ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A1
- Proportion of baseline seropositive subjects (based on central lab test) with TEAEs and severity of TEAEs [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Incidence of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Severity of symptomatic SARS-CoV-2 infection in seronegative and seropositive participants (based on central lab test) in both the EAP and follow-up periods [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
- Concentrations of REGN10933 in serum over time and selected PK parameters in seronegative and seropositive participants (based on central lab test) [ Time Frame: Up to 8 months ]
Pharmacokinetic (PK) parameters may include, but are not limited to:
- Maximum observed plasma concentration (Cmax)
- Cmax/Dose
- Time of maximum observed plasma concentration (tmax)
- Time of Clast (tlast)
- Last measurable plasma concentration (Clast)
- Area under plasma concentration-time curve from time 0 to infinity (AUCinf)
- AUCinf/Dose
- Elimination half-life (t1/2)
- Concentration in serum 28 days (C28) after dosing)
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Concentrations of REGN10987 in serum over time and selected PK parameters in seronegative and seropositive participants (based on central lab test) [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10933 over time in seronegative and seropositive participants (based on central lab test) [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Immunogenicity as measured by neutralizing anti-drug antibodies (NAbs) to REGN10933 over time in seronegative and seropositive participants (based on central lab test) [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Immunogenicity as measured by anti-drug antibodies (ADA) to REGN10987 over time in seronegative and seropositive participants (based on central lab test) [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Immunogenicity as measured by neutralizing anti-drug antibodies (NAbs) to REGN10987 over time in seronegative and seropositive participants (based on central lab test) [ Time Frame: Up to 8 months ]
For subjects who are seronegative at baseline (based on central lab test), unless stated otherwise.
Cohort A and Cohort A1
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Number of weeks of symptomatic SARS-CoV-2 infection (broad-term) within 14 days of a positive RT-qPCR at baseline or during the EAP [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Proportion of participants who subsequently develop signs and symptoms (CDC definition) within 14 days of a positive RT-qPCR at baseline or during the EAP [ Time Frame: Up to 1 month ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Proportion of participants who subsequently develop signs and symptoms (strict-term) within 14 days of a positive RT-qPCR at baseline or during the EAP [ Time Frame: Up to 1 month ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Number of weeks of symptomatic SARS-CoV-2 infection (CDC definition) within 14 days of a positive RT-qPCR at baseline or during the EAP [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Number of weeks of symptomatic SARS CoV-2 infection (strict-term) within 14 days of a postive RT-qPCR at baseline or during the EAP [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Change in viral load (log10 copies/mL) from baseline to day 8 visit in NP swab samples [ Time Frame: Up to day 8 visit ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Change in viral load (log10 copies/mL) from baseline to day 15 visit in NP swab samples [ Time Frame: Up to day 15 visit ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Time-weighted average change from baseline in viral load (log10 copies/mL) in NP swab samples until the day 22 visit [ Time Frame: Day 22 visit ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Area under the curve (AUC) in viral load (log10 copies/mL) in NP swab samples from baseline to the first confirmed negative test [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Maximum SARS-CoV-2 RT-qPCR viral load (log10 copies/mL) in NP swab samples during the EAP [ Time Frame: Up to 1 month ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Number of medically attended visits in emergency rooms or urgent care centers related to RT-qPCR confirmed SARS-CoV-2 infection that has an onset at baseline or during the EAP [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Proportion of participants requiring medically attended visits in emergency rooms or urgent care centers related to a RT-qPCR confirmed SARS CoV-2 infection that has an onset at baseline or during the EAP [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Proportion of participants hospitalized related to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset at baseline or during the EAP [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Number of days of hospital and intensive care unit (ICU) stay in participants hospitalized for a RT-qPCR confirmed SARS-CoV-2 infection that has an onset at baseline or during the EAP [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Number of days missed for daily responsibilities (where applicable) due to a RT-qPCR confirmed SARS-CoV-2 infection that has an onset at baseline or during the EAP [ Time Frame: Up to 8 months ]
Daily responsibilities including work (employed adults) or school (students), or family obligations/responsibilities (childcare or eldercare)
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Proportion of participants with at least one COVID-19 related hospitalization or emergency room visit associated with a positive RT-qPCR at baseline or during the EAP, or all-cause death [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Proportion of participants with TEAEs and severity of TEAEs [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Incidence of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1
- Severity of symptomatic SARS-CoV-2 infection in both the EAP and follow-up periods [ Time Frame: Up to 8 months ]
For all subjects irrespective of baseline serology status (based on central lab test)
Cohort B and Cohort B1

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Key Inclusion Criteria:
- Adult subjects 18 years of age (irrespective of weight) and above at the signing of informed consent or adolescent participants ≥12 to <18 years of age, or pediatric participants <12 years of age at the signing of the assent (parent/guardian sign the informed consent)
- Asymptomatic household contact with exposure to an individual with a diagnosis of SARS-CoV-2 infection (index case). To be included in the study, participants must be randomized within 96 hours of collection of the index cases' positive SARS-COV-2 diagnostic test sample
- Participant anticipates living in the same household with the index case until study day 29
- Is judged by the investigator to be in good health based on medical history and physical examination at screening/baseline, including participants who are healthy or have a chronic, stable medical condition
- Willing and able to comply with study visits and study-related procedures/assessments.
- Provide informed consent signed by study participant or legally acceptable representative.
Key Exclusion Criteria:
- History of prior positive SARS-CoV-2 RT-PCR test or positive SARS-CoV-2 serology test at any time before the screening
- Participant has lived with individuals who have had previous SARS-CoV-2 infection or currently lives with individuals who have SARS-CoV-2 infection, with the exception of the index case(s), the first individual(s) known to be infected in the household
- Active respiratory or non-respiratory symptoms consistent with COVID-19
- History of respiratory illness with sign/symptoms of SARS-CoV-2 infection, in the opinion of the investigator, within the prior 6 months to screening
- Nursing home resident
- Any physical examination findings, and/or history of any illness, concomitant medications or recent live vaccines that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the participant by their participation in the study
Note: Other protocol-defined Inclusion/ Exclusion criteria apply

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04452318

Study Director: | Clinical Trial Management | Regeneron Pharmaceuticals |
Responsible Party: | Regeneron Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT04452318 |
Other Study ID Numbers: |
R10933-10987-COV-2069 2020-003654-71 ( EudraCT Number ) |
First Posted: | June 30, 2020 Key Record Dates |
Last Update Posted: | October 7, 2021 |
Last Verified: | October 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Time Frame: | Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. |
Access Criteria: | Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry). |
URL: | https://vivli.org/ |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Asymptomatic Individuals at risk of exposure to SARS-CoV-2 Household Contacts of a Person Infected with SARS-CoV-2 |
COVID-19 Infections Respiratory Tract Infections Pneumonia, Viral Pneumonia Virus Diseases |
Coronavirus Infections Coronaviridae Infections Nidovirales Infections RNA Virus Infections Lung Diseases Respiratory Tract Diseases |